Mereo BioPharma to Present at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019
LONDON, March 05, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, is pleased to announce that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Cowen and Company 39th Annual Healthcare Conference to be held March 12, 2019 in Boston.
Mereo BioPharma Presentation Details
Date: Tuesday, 12 March 2019
Time: 8:40-9:10 AM ET (1:40-2:10 PM BST)
Location: The Boston Marriott Copley Place, 110 Huntington Ave, Boston, MA 02110
Track & Room: Vineyard
A live audio webcast of the presentation can be accessed through the Events & Conferences section of the company’s website at . An archived replay of the webcast will be available on the company’s website for two weeks following the live presentation.
About Mereo
Mereo is a biopharmaceutical company focused on the development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. In December 2018, Mereo announced the proposed combination of Mereo and OncoMed Pharmaceuticals, with the transaction expected to close in the second quarter of 2019. Each of Mereo's four product candidates has previously generated positive clinical data for Mereo's target indication or in a related indication. Since inception Mereo has commenced large, randomised, placebo-controlled Phase 2 clinical trials for all four of the product candidates:
- BPS-804 for osteogenesis imperfecta (OI). Mereo recently announced completion of enrolment with 112 adult patients in a Phase 2b dose ranging study with some initial data at the top dose expected in the Q2 2019 and top-line dose ranging data in late 2019. A pediatric Phase 3 study design has also been approved by the EMA. BPS-804 has orphan designation in the US and EU and has been accepted into the PRIME and Adaptive Pathways in EU;
- MPH-966 for alpha-1 antitrypsin deficiency (AATD). Mereo recently announced first patient in a Phase 2 dose ranging study in the US with data expected in late 2019;
- BCT-197 for acute exacerbations of COPD (AECOPD). Mereo announced positive Phase 2 data in May 2018; and
- BGS-649 for hypogonadotropic hypogonadism (HH). Mereo announced positive top-line Phase 2b data in March 2018 and positive results from the Phase 2b safety extension study in December 2018.
For Further Enquiries:
| Mereo | +44 (0)333 023 7300 |
| Denise Scots-Knight, Chief Executive Officer | |
| Richard Jones, Chief Financial Officer | |
| Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo) | +44 (0)20 7894 7000 |
| Phil Davies | |
| Will Goode | |
| RBC Capital Markets (Joint Broker to Mereo) | +44 (0)20 7653 4000 |
| Rupert Walford | |
| Jamil Miah | |
| FTI Consulting (Public Relations Adviser to Mereo) | |
| Simon Conway | +44 (0)20 3727 1000 |
| Brett Pollard | |
| Burns McClellan (US Public Relations Adviser to Mereo) | +01 (0) 212 213 0006 |
| Lisa Burns | |
| Jill Steier |
